Journal rankings · indicator year 2023
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Subfield ranking · 2023
Oncology journal rankings 2023
245 ranked journals · Subfield in Medicine
Oncology has 245 ranked journals in 2023. The median journal has an OJR of 0.75, below the world average of 1.00, down 0.02 on 2022; Q1 starts at OJR 1.17. The top three are CA A Cancer Journal for Clinicians, Nature Medicine, and The Lancet Oncology.
Ranks and citation indicators: 2023. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2020–2022, the window the 2023 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields of Medicine (42)
- Surgery993
- Pulmonary and Respiratory Medicine367
- Public Health, Environmental and Occupational Health313
- Cardiology and Cardiovascular Medicine293
- Infectious Diseases259
- Oncology245
- Epidemiology199
- Neurology174
- Physiology161
- Radiology, Nuclear Medicine and Imaging161
- Endocrinology, Diabetes and Metabolism159
- Psychiatry and Mental health144
Show all 42 subfields
- Orthopedics and Sports Medicine124
- Ophthalmology105
- Pediatrics, Perinatology and Child Health99
- Dermatology97
- Obstetrics and Gynecology90
- Hematology84
- Rheumatology67
- Nephrology65
- Reproductive Medicine56
- Complementary and alternative medicine54
- Pharmacology52
- Emergency Medicine44
- Geriatrics and Gerontology38
- Rehabilitation35
- Otorhinolaryngology34
- Hepatology32
- Pathology and Forensic Medicine29
- Immunology and Allergy25
- Critical Care and Intensive Care Medicine22
- Genetics22
- Anesthesiology and Pain Medicine14
- Urology12
- Gastroenterology8
- Internal Medicine6
- Health Informatics5
- Transplantation3
- Family Practice2
- Anatomy0
- Biochemistry0
- Microbiology0
245 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2022. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2020–2022, the window the 2023 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2020–2022 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2014 to 2023. | Compare |
|---|---|---|---|---|---|---|---|
1CA A Cancer Journal for CliniciansOAWiley · United States | 147.65Q1 | 694.53 143.18 up from 2022 | 89 | 100% | $4,330 | ||
2Nature MedicineNature Portfolio · United States | 12.39Q1 | 41.03 17.71 down from 2022 | 1,073 | 54% | $12,690 | ||
3The Lancet OncologyElsevier BV · United Kingdom | 7.50Q1 | 21.08 4.65 down from 2022 | 1,008 | 35% | $7,280 | ||
4Journal of Hematology & OncologyOABioMed Central · United Kingdom | 7.25Q1 | 24.38 0.44 down from 2022 | 527 | 100% | $4,990 | ||
5Journal of Clinical OncologyLippincott Williams & Wilkins · United States | 7.22Q1 | 20.28 1.84 down from 2022 | 1,437 | 45% | — | ||
6Cancer CellCell Press · Netherlands | 6.59Q1 | 21.68 3.98 down from 2022 | 571 | 100% | $10,400 | ||
7Cancer DiscoveryAmerican Association for Cancer Research · United States | 6.50Q1 | 24.60 3.66 up from 2022 | 577 | 31% | — | ||
8Nature Reviews Clinical OncologyNature Portfolio · United Kingdom | 6.27Q1 | 32.92 2.70 up from 2022 | 369 | 14% | — | ||
9Annals of OncologyElsevier BV · Netherlands | 4.83Q1 | 17.06 0.06 down from 2022 | 995 | 100% | $5,080 | ||
10Nature CancerNature Portfolio · United States | 4.60Q1 | 15.97 1.13 up from 2022 | 431 | 52% | $12,690 | ||
11Journal of the National Comprehensive Cancer NetworkNational Comprehensive Cancer | 4.44Q1 | 13.54 0.74 up from 2022 | 570 | 56% | — | ||
12Journal of the National Cancer CenterOAElsevier BV · China | 3.68Q1 | 10.02 2.98 up from 2022 | 65 | 100% | $2,160 | ||
13JAMA OncologyAmerican Medical Association · United States | 3.37Q1 | 9.62 1.48 down from 2022 | 1,192 | 52% | — | ||
14Seminars in Cancer BiologyElsevier BV · United States | 3.22Q1 | 11.56 1.56 up from 2022 | 580 | 46% | $6,060 | ||
15European Journal of EpidemiologySpringer Science+Business Media · Italy | 3.17Q1 | 8.06 6.96 down from 2022 | 321 | 80% | $3,690 | ||
16Clinical Cancer ResearchAmerican Association for Cancer Research · United States | 3.06Q1 | 9.61 0.82 down from 2022 | 1,904 | 63% | — | ||
17Cell Reports MedicineOAElsevier BV · United States | 3.02Q1 | 9.87 3.55 down from 2022 | 565 | 100% | $5,620 | ||
18Journal for ImmunoTherapy of CancerOABMJ · United Kingdom | 2.99Q1 | 10.81 0.38 down from 2022 | 1,576 | 100% | $2,490 | ||
19Cancer Treatment ReviewsElsevier BV · United Kingdom | 2.91Q1 | 10.44 2.52 down from 2022 | 303 | 64% | $4,910 | ||
20JNCI Journal of the National Cancer InstituteOxford University Press · United States | 2.82Q1 | 8.46 0.94 down from 2022 | 513 | 94% | $5,436 | ||
21npj Precision OncologyOANature Portfolio · United Kingdom | 2.51Q1 | 7.89 0.99 down from 2022 | 226 | 100% | $4,090 | ||
22ImmunoTargets and TherapyOADove Medical Press · New Zealand | 2.44Q1 | 7.68 0.81 down from 2022 | 62 | 100% | $2,320 | ||
23Breast Cancer ResearchOABioMed Central · United Kingdom | 2.35Q1 | 6.99 1.32 down from 2022 | 334 | 100% | $4,190 | ||
24American Society of Clinical Oncology Educational BookAmerican Society of Clinical Oncology · United States | 2.34Q1 | 7.38 1.91 up from 2022 | 217 | 79% | — | ||
25British Journal of CancerSpringer Nature · United Kingdom | 2.25Q1 | 6.79 1.49 down from 2022 | 1,318 | 100% | $5,190 | ||
26Cancer Immunology ResearchAmerican Association for Cancer Research · United States | 2.16Q1 | 7.00 1.70 down from 2022 | 388 | 40% | — | ||
27MedElsevier BV · United States | 2.04Q1 | 6.57 2.85 down from 2022 | 259 | 100% | $9,350 | ||
28ESMO OpenOAElsevier BV · Netherlands | 2.01Q1 | 7.23 0.11 up from 2022 | 711 | 100% | $3,910 | ||
29npj Breast CancerOANature Portfolio · United States | 1.95Q1 | 7.33 0.71 up from 2022 | 348 | 100% | $3,790 | ||
30European Journal of CancerElsevier BV · United Kingdom | 1.93Q1 | 6.83 0.63 down from 2022 | 1,455 | 51% | $4,270 | ||
31International Journal of CancerWiley · United States | 1.91Q1 | 6.29 0.37 down from 2022 | 1,339 | 74% | $5,030 | ||
32Current Oncology ReportsSpringer Science+Business Media · United States | 1.89Q1 | 5.70 0.14 up from 2022 | 455 | 44% | $5,090 | ||
33CancerWiley · United States | 1.87Q1 | 5.10 0.39 down from 2022 | 1,679 | 87% | $4,790 | ||
34Clinical Pharmacology & TherapeuticsWiley · United States | 1.85Q1 | 5.61 0.08 up from 2022 | 950 | 72% | $4,410 | ||
35Current Treatment Options in OncologySpringer Science+Business Media · United States | 1.74Q1 | 4.57 0.65 down from 2022 | 333 | 37% | $4,890 | ||
36OncoImmunologyOALandes Bioscience · United States | 1.67Q1 | 6.48 0.84 down from 2022 | 645 | 100% | $2,913 | ||
37World Journal of OncologyOAElmer Press Inc. · Canada | 1.62Q1 | 2.80 3.33 down from 2022 | 109 | 100% | — | ||
38Expert Opinion on Investigational DrugsTaylor & Francis · United Kingdom | 1.60Q1 | 5.36 0.54 down from 2022 | 313 | 29% | — | ||
39Chinese Journal of Cancer ResearchOAAME Publishing Company · China | 1.59Q1 | 4.29 1.17 down from 2022 | 177 | 100% | — | ||
40The OncologistOAAlphaMed Press · United Kingdom | 1.53Q1 | 4.83 0.53 down from 2022 | 1,014 | 100% | $3,852 | ||
41Cancer Biology and MedicineOAChinese Anti-Cancer Association · China | 1.51Q1 | 5.24 0.58 down from 2022 | 283 | 100% | $1,500 | ||
42Molecular Cancer TherapeuticsAmerican Association for Cancer Research · United States | 1.48Q1 | 5.20 0.34 down from 2022 | 592 | 16% | — | ||
43CancersOAMultidisciplinary Digital Publishing Institute · Switzerland | 1.45Q1 | 5.05 0.60 down from 2022 | 16,594 | 100% | $3,499 | ||
44Cancer Immunology ImmunotherapyOASpringer Science+Business Media · Germany | 1.40Q1 | 5.18 0.77 down from 2022 | 850 | 100% | $4,590 | ||
45Trends in cancerElsevier BV · United States | 1.39Q1 | 8.93 1.35 down from 2022 | 395 | 59% | $7,030 | ||
46JCO Global OncologyOALippincott Williams & Wilkins · United States | 1.37Q1 | 3.93 1.16 down from 2022 | 531 | 100% | $2,472 | ||
47Critical Reviews in Oncology/HematologyElsevier BV · Netherlands | 1.36Q1 | 5.71 0.50 down from 2022 | 651 | 42% | $4,190 | ||
48JCO Clinical Cancer InformaticsLippincott Williams & Wilkins · United States | 1.35Q1 | 3.27 1.82 down from 2022 | 322 | 71% | — | ||
49Therapeutic Advances in Medical OncologyOASAGE Publishing · United Kingdom | 1.32Q1 | 4.76 0.70 down from 2022 | 562 | 100% | $2,800 | ||
50Cancer Research and TreatmentOAKorean Cancer Association · South Korea | 1.31Q1 | 4.00 0.01 up from 2022 | 368 | 100% | — |
Subfields of Medicine, with Oncology highlighted.
- Surgery993
- Pulmonary and Respiratory Medicine367
- Public Health, Environmental and Occupational Health313
- Cardiology and Cardiovascular Medicine293
- Infectious Diseases259
- Oncology245
- Epidemiology199
- Neurology174
- Physiology161
- Radiology, Nuclear Medicine and Imaging161
- Endocrinology, Diabetes and Metabolism159
- Psychiatry and Mental health144
- Orthopedics and Sports Medicine124
- Ophthalmology105
- Pediatrics, Perinatology and Child Health99
- Dermatology97
- Obstetrics and Gynecology90
- Hematology84
- Rheumatology67
- Nephrology65
- Reproductive Medicine56
- Complementary and alternative medicine54
- Pharmacology52
- Emergency Medicine44
- Geriatrics and Gerontology38
- Rehabilitation35
- Otorhinolaryngology34
- Hepatology32
- Pathology and Forensic Medicine29
- Immunology and Allergy25
- Critical Care and Intensive Care Medicine22
- Genetics22
- Anesthesiology and Pain Medicine14
- Urology12
- Gastroenterology8
- Internal Medicine6
- Health Informatics5
- Transplantation3
- Family Practice2
- Anatomy0
- Biochemistry0
- Microbiology0
Journals
Citations made in 2023. Corpus-wide, 88.9% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
72 additional Oncology journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2020–2022, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2023. Publication window: 2020–2022. How these summaries are calculated
- Ranked journals
- 245
- Window papers (baseline)
- 167,602 +37.5% from indicator year 2020
- Median OJR
- 0.750 -9.5% from indicator year 2020
- Rising journals (2025)
- 20
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2020–2022 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 82 | 88 | 96 | 103 | 109 | 120 | 120 | 126 | 127 | 134 | 141 | 150 | 153 | 170 | 179 | 188 | 198 | 213 | 224 | 234 | 238 | 239 | 245 | 245 | 243 | 242 | |
| Window papers (baseline) | 37,821 | 41,430 | 44,340 | 47,392 | 49,058 | 53,111 | 57,002 | 62,106 | 66,087 | 71,283 | 77,009 | 82,075 | 86,189 | 88,804 | 93,912 | 98,660 | 102,921 | 105,891 | 109,984 | 115,044 | 121,890 | 139,666 | 156,942 | 167,602 | 163,907 | 160,807 | |
| Median OJR | 0.55 | 0.62 | 0.70 | 0.799 | 0.805 | 0.831 | 0.85 | 0.90 | 0.94 | 0.93 | 1.010 | 0.95 | 1.006 | 0.974 | 0.972 | 0.967 | 0.832 | 0.84 | 0.82 | 0.79 | 0.829 | 0.830 | 0.77 | 0.750 | 0.73 | 0.748 |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.